NAV
$111.44
AUM
$941.8M
Expense Ratio
-
Dividend Yield
1.97%
Beta
0.44
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +6.67% | +4.07% | +6.53% | +25.34% | +15.14% | +10.74% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 22.34% |
| 2 | NVS | Novartis AG ADR | 10.53% |
| 3 | MRK | Merck & Co Inc | 9.51% |
| 4 | NVO | Novo Nordisk AS ADR | 5.93% |
| 5 | PFE | Pfizer Inc | 4.85% |
| 6 | BMY | Bristol-Myers Squibb Co | 4.34% |
| 7 | SNY | Sanofi SA ADR | 4.26% |
| 8 | GSK | GSK PLC ADR | 4.17% |
| 9 | AZN.L | AstraZeneca PLC | 4.12% |
| 10 | ABBV | AbbVie Inc | 4.10% |
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Inception Date: 2011-12-20